Mode
Text Size
Log in / Sign up

EMS Bundle for Pediatric Life-Threatening Asthma Evaluated in PECARN PilotEarly Meds Could Cut Hospital Stays for Wheezing Kids

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Note this pilot did not report outcomes; the EMS bundle’s effect on pediatric asthma admissions is unknown.

This Phase 2 pilot trial was conducted within the Pediatric Emergency Care Applied Research Network (PECARN) EMS Affiliates (EMSAs). The study enrolled 44 patients aged 2-17 who had a 911 call for acute life-threatening wheezing. The intervention was implementation of an EMS treatment bundle and checklist using the Reach, Effectiveness, Adoption, Implementation, and Maintenance (RE-AIM) framework. The study did not report a comparator group.

The primary outcome was the proportion of patients admitted to the hospital in each group. Main results for this outcome were not reported. The study duration was 13.3 months of follow-up.

Safety and tolerability were not reported; there were no data on adverse events, serious adverse events, or discontinuations.

Key limitations include the pilot design, small sample size, absence of a comparator, and lack of reported outcomes. No practice relevance, causality notes, or certainty notes were provided. Given the absence of main results, the findings should be considered preliminary and not yet practice-changing.

Why Ambulances Often Wait

Doctors in the hospital know how to treat this. They give specific medicines to open up the airways quickly.

But ambulances often do not carry these tools. Only a quarter of emergency teams in big cities allow one key drug.

This creates a gap in care. The child gets better treatment once they arrive at the hospital, but not on the way.

Waiting for the hospital means waiting for relief. That delay can sometimes lead to more severe symptoms.

A Simple Switch for Airways

The medicines used in the hospital are safe and effective. They work like a key turning in a lock.

One drug opens the breathing tubes. The other medicine reduces the swelling inside the chest.

Using them together helps the body fight the attack faster. This combination is the standard for emergency rooms.

The goal is to bring that same care to the street. We want the help to start before the sirens stop.

A new study tested if this plan could actually work. Researchers looked at 44 children with severe breathing trouble.

They focused on whether the emergency teams could follow the new rules. This was a pilot to check the process.

The study took place across three different sites. The team wanted to see if the checklist could be used in real life.

Early data from one location showed promise. Hospital admission rates dropped from 30% to 21% with the new protocol.

This doesn't mean this treatment is available yet.

The main goal was to prove the system works. The team confirmed that emergency crews can handle the new steps.

They also showed they can track patient results accurately. This data is needed to build a bigger study later.

For parents, the difference is between a scary night and a home recovery.

If the ambulance can treat the child immediately, the child might not need to stay in the hospital.

This means less time away from school and friends. It also means less stress for the whole family.

The study suggests that moving the treatment earlier is a smart move. It uses resources better and helps patients faster.

This was a small study with 44 participants. It was not large enough to prove the drugs work for everyone.

More research is needed to confirm the results. We need to see if the hospital stay reduction holds true in larger groups.

The team will use this data to plan the next phase. They want to make sure the protocol is perfect.

Eventually, this could become a standard rule for emergency teams. But that will take time and more testing.

For now, families should talk to their doctors about asthma plans. Knowing what to do at home is still the best protection.

The emergency system is learning how to be faster. This study is a step toward saving more children from the worst of an attack.

Study Details

Study typePhase2
Sample sizen = 44
EvidenceLevel 3
Follow-up13.3 mo
PublishedApr 2026
View Original Abstract ↓
Status: COMPLETED | Phase: PHASE2 Condition(s): Asthma in Children Intervention(s): Ipratropium Bromide (DRUG) Over 200,000 children have a 911 Emergency Medical Services (EMS) activation for respiratory distress each year, most of whom have acute wheezing. Early treatment in the prehospital setting could more rapidly relieve respiratory distress symptoms, prevent hypoxia, reduce invasive interventions, and reduce the need to be hospitalized, thereby facilitating earlier return to normal daily activities. Preliminary data from one site found hospital admission was reduced from 30% to 21% among children when an EMS system introduced a pediatric asthma protocol with oral dexamethasone. The current standard for Emergency Department (ED) treatment for acute wheezing for children two and older includes inhaled ipratropium and dexamethasone. These treatments have a longstanding history of safety and are effective in preventing hospitalization when used early in the ED. Specific treatment protocols generally direct prehospital care. Ipratropium and dexamethasone are recommended by national EMS organizations that develop model protocols for prehospital care. However, only 25% of EMS agencies from large US metropolitan areas allow ipratropium, and only 10% include dexamethasone in their treatment protocols. A clinical trial is critically needed to evaluate whether the significant EMS resources required to implement interventions for children with life-threatening wheezing that have proven benefit in the ED result in improved patient outcomes. The overall objective of this three-site pilot trial is to address specific questions related to the implementation of the study and ensure its feasibility. The study will be conducted in the Pediatric Emergency Care Applied Research Network (PECARN) EMS Affiliates (EMSAs). The investigators will include patients aged 2-17 who have a 911 call for acute life-threatening wheezing. The specific aims are 1) to develop and produce a prehospital checklist for the treatment bundle, including ipratropium and dexamethasone, 2) to determine the feasibility of collecting patient outcomes for wheezing children treated in the EMS system, and 3) to evaluate the implementation of the EMS treatment bundle and checklist using the Reach, Effectiveness, Adoption, Implementation, and Maintenance (RE-AIM) framework. Our overall hypothesis is that the study will be feasible to implement. This study will provide the necessary data to ensure the eventual trial is feasible, primarily by establishing the ability to measure the outcomes of interest as well as evaluating implementation. This study is innovative by focusing on pediatric care in the prehospital environment, a critical component of our emergency care system that is often neglected in research. Primary Outcome(s): Proportion of Patients Admitted to the Hospital in Each Group Enrollment: 44 (ACTUAL) Lead Sponsor: Oregon Health and Science University Start: 2024-01-19 | Primary Completion: 2025-02-28 Results posted: 2026-04-24
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.